The implication of CRISPR/Cas9 genome editing technology in combating human oncoviruses

• Published in: Journal of medical virology Vol. 91; no. 1; pp. 1 - 13
• Main Authors: Gilani, Usman, Shaukat, Memoona, Rasheed, Arisha, Shahid, Mehak, Tasneem, Fareeda, Arshad, Muhammad, Rashid, Naeem, Shahzad, Naveed
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.01.2019
• Subjects: Biomedical Research - trends; Carcinogenesis; Carcinogens; Clinical aspects; Clustered Regularly Interspaced Short Palindromic Repeats; Collating; CRISPR; CRISPR-Associated Protein 9 - metabolism; CRISPR/Cas9; DNA targeting; Editing; Epstein-Barr virus; Gene Editing - methods; Gene sequencing; Genetic Therapy - methods; Genome editing; Genomes; Hepatitis; Hepatitis B; HIV; Human immunodeficiency virus; Human papillomavirus; Humans; Immune system; Infections; Latency; Molecular Targeted Therapy - methods; Oncogenic Viruses - genetics; oncoviruses; Papilloma viruses; Parasites; Proteins; Sarcoma; Technology; Tumor Virus Infections - therapy; Tumor viruses; Tumors; Virology; Viruses; genome editing; DNA targeting; oncoviruses; CRISPR/Cas9
• ISSN: 0146-6615; 1096-9071
• DOI: 10.1002/jmv.25292

It is evidenced that 20% of all tumors in humans are caused by oncoviruses, including human papilloma viruses, Epstein‐Barr virus, Kaposi sarcoma virus, human polyomaviruses, human T‐lymphotrophic virus‐1, and hepatitis B and C viruses. Human immunodeficiency virus is also involved in carcinogenesis, although not directly, but by facilitating the infection of many oncoviruses through compromising the immune system. Being intracellular parasites with the property of establishing latency and integrating into the host genome, these viruses are a therapeutic challenge for biomedical researchers. Therefore, strategies able to target nucleotide sequences within episomal or integrated viral genomes are of prime importance in antiviral or anticancerous armamentarium. Recently, clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated protein 9 (Cas9) has emerged as a powerful genome editing tool. Standing out as a precise and efficient oncoviruses method, it has been extensively applied in recent experimental ventures in the field of molecular medicine, particularly in combating infections including tumor inducing viruses. This review is aimed at collating the experimental and clinical advances in CRISPR/Cas9 technology in terms of its applications against oncoviruses. Primarily, it will focus on the application of CRISPR/Cas9 in combating tumor viruses, types of mechanisms targeted, and the significant outcomes till date. The technical pitfalls of the CRISPR/Cas9 and the comparative approaches in evaluating this technique with respect to other available alternatives are also described briefly. Furthermore, the review also discussed the clinical aspects and the ethical, legal, and social issues associated with the use of CRISPR/Cas9.